Prosthesis‐patient mismatch after transcatheter implantation of contemporary balloon‐expandable and self‐expandable valves in small aortic annuli

Abstract

AbstractBackgroundEvidence of clinical impact of PPM after TAVI is conflicting and might vary according to the type of valve implanted.AimsTo assess the clinical impact of prosthesis‐patient mismatch (PPM) after transcatheter aortic valve implantation (TAVI) with balloon‐expandable (BEV) and self‐expandable valves (SEV) in patients with small annuli.MethodsTAVI‐SMALL 2 enrolled 628 patients in an international retrospective registry, which included patients with severe aortic stenosis and small annuli (annular perimeter <72 mm or area <400 mm2) treated with transfemoral TAVI at 16 high‐volume centers between 2011 and 2020. Analyses were performed comparing patients with less than moderate (n = 452), moderate (n = 138), and severe PPM (n = 38). Primary endpoint was incidence of all‐cause mortality. Predictors of all‐cause mortality and PPM were investigated.ResultsAt a median follow‐up of 380 days (interquartile range: 210–709 days), patients with severe PPM, but not moderate PPM, had an increased risk of all‐cause mortality when compared with less than moderate PPM (log‐rank p = 0.046). Severe PPM predicted all‐cause mortality in patients with BEV (hazard ratio [HR]: 5.20, 95% confidence interval [CI]: 1.27–21.2) and intra‐annular valves (IAVs, HR: 4.23, 95% CI: 1.28–14.02), and it did so with borderline significance in the overall population (HR: 2.89, 95% CI: 0.95–8.79). Supra‐annular valve (SAV) implantation was the only predictor of severe PPM (odds ratio: 0.33, 95% CI: 0.13–0.83).ConclusionsPatients with small aortic annuli and severe PPM after TAVI have an increased risk of all‐cause mortality at early term follow‐up, especially after IAV or BEV implantation. TAVI with SAV protected from severe PPM.